The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“Class I and II HDACs, in addition to histones, have many nonhistone protein targets, including transcription factors and proteins that regulate cell proliferation, migration and deat”
BackgroundHistone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“In humans, 18 HDAC enzymes have been identified and categorized into three main classes based on their homology to yeast deacetylase”
BackgroundSelf-citationYoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Self-citationFriend, C., Scher, W., Holland, J. G., & Sato, T. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.2.378 · Cited by 1,352
Epigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Self-citationA class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Self-citationKelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Self-citation
Cited by
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
“The property of vorinostat to induce differentiation of transformed cells was discovered before identifying its inhibitory activity against HDACs (Marks and Breslow, 2007).”
BackgroundInfluentialSelf-citationEpigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Activity-Based Protein Profiling: From Enzyme Chemistry to Proteomic Chemistry
Cravatt, B. F., Wright, A. T., & Kozarich, J. W. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.124125 · Cited by 1,270
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X.-J., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,230
Histone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,164
Self-citationNatural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Bocklandt, S., Lin, W., Sehl, M. E., Sánchez, F. J., Sinsheimer, J. S., Horvath, S., & Vilain, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014821 · Cited by 1,012
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Histone deacetylase inhibitors: Potential in cancer therapy
Marks, P. A., & Xu, W. ‐. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22185 · Cited by 712
Self-citationChemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
Structure of Hdac3 Bound to Co-Repressor and Inositol Tetraphosphate
Watson, P. J., Fairall, L., Santos, G. M., & Schwabe, J. W. R. (2012) · Nature · doi:10.1038/nature10728 · Cited by 505
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Recent applications of multicomponent reactions in medicinal chemistry
Slobbe, P., Ruijter, E., & Orru, R. V. A. (2012) · MedChemComm · doi:10.1039/c2md20089a · Cited by 484
Jares, P., Colomer, D., & Campo, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2230 · Cited by 466
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
Metabolic Regulation by Lysine Malonylation, Succinylation, and Glutarylation
Hirschey, M. D., & Zhao, Y. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r114.046664 · Cited by 427
HDAC expression and clinical prognosis in human malignancies
Weichert, W. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.10.047 · Cited by 409
Spina, C. A., Anderson, J., Archin, N. M., Bosque, A., Chan, J., Famiglietti, M., Greene, W. C., Kashuba, A., Lewin, S. R., Margolis, D. M., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003834 · Cited by 403
Chemical mechanisms of histone lysine and arginine modifications
Smith, B. C., & Denu, J. M. (2009) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2008.06.005 · Cited by 390
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
Bhaskara, S., Chyla, B. J., Amann, J. M., Knutson, S. K., Cortez, D., Sun, Z.-W., & Hiebert, S. W. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.030 · Cited by 372
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
Lee, J.-H., Choy, M. L., Ngo, L., Foster, S. S., & Marks, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008522107 · Cited by 363
Self-citationWeichert, W., Röske, A., Gekeler, V., Beckers, T., Ebert, M. P., Pross, M., Dietel, M., Denkert, C., & Röcken, C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70004-4 · Cited by 360
Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A., Nebozhyn, M., Fantin, V. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0694 · Cited by 358
An overview of benzo [b] thiophene-based medicinal chemistry
Keri, R. S., Chand, K., Budagumpi, S., Balappa Somappa, S., Patil, S. A., & Nagaraja, B. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.038 · Cited by 356
Photoaffinity Labeling in Target- and Binding-Site Identification
Smith, E., & Collins, I. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.152 · Cited by 352
Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.02.006 · Cited by 352
Roger, T., Lugrin, J., Le Roy, D., Goy, G., Mombelli, M., Koessler, T., Ding, X. C., Chanson, A.-L., Reymond, M. K., Miconnet, I., et al. (2011) · Blood · doi:10.1182/blood-2010-05-284711 · Cited by 341
The timeline of epigenetic drug discovery: from reality to dreams
Ganesan, A., Arimondo, P. B., Rots, M. G., Jeronimo, C., & Berdasco, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0776-0 · Cited by 341
Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid
Archin, N. M., Espeseth, A., Parker, D., Cheema, M., Hazuda, D., & Margolis, D. M. (2009) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2008.0191 · Cited by 336
Epigenetic factors in aging and longevity
Gravina, S., & Vijg, J. (2010) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-009-0730-7 · Cited by 329
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation
Parmigiani, R. B., Xu, W. S., Venta-Perez, G., Erdjument-Bromage, H., Yaneva, M., Tempst, P., & Marks, P. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803749105 · Cited by 321
Self-citationHistone Deacetylases and Mechanisms of Regulation of Gene Expression
Chen, H. P., Zhao, Y. T., & Zhao, T. C. (2015) · Critical Reviews in Oncogenesis · doi:10.1615/critrevoncog.2015012997 · Cited by 306
Copper-Mediated Amidation of Heterocyclic and Aromatic C−H Bonds
Wang, Q., & Schreiber, S. L. (2009) · Organic Letters · doi:10.1021/ol902079g · Cited by 303
Nonhistone protein acetylation as cancer therapy targets
Singh, B. N., Zhang, G., Hwa, Y. L., Li, J., Dowdy, S. C., & Jiang, S.-W. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.62 · Cited by 300
Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, H., Ryan, G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4262 · Cited by 297
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Marks, P. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.510514 · Cited by 281
Self-citationHistone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Licciardi, P., Ververis, Hiong, & Karagiannis (2013) · Biologics: Targets and Therapy · doi:10.2147/btt.s29965 · Cited by 274
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect
Lara, E., Mai, A., Calvanese, V, Altucci, L., Lopez-Nieva, P., Martinez-Chantar, M. L., Varela-Rey, M., Rotili, D., Nebbioso, A., Ropero, S., et al. (2009) · Oncogene · doi:10.1038/onc.2008.436 · Cited by 259
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis
Hutt, D. M., Herman, D., Rodrigues, A. P. C., Noel, S., Pilewski, J. M., Matteson, J., Hoch, B., Kellner, W., Kelly, J. W., Schmidt, A., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.275 · Cited by 252
Therapeutic potential for HDAC inhibitors in the heart
McKinsey, T. A. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134712 · Cited by 230
Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191
Halili, M. A., Andrews, M. R., Labzin, L. I., Schroder, K., Matthias, G., Cao, C., Lovelace, E., Reid, R. C., Le, G. T., Hume, D. A., et al. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0509363 · Cited by 186
Foxk proteins repress the initiation of starvation-induced atrophy and autophagy programs
Bowman, C. J., Ayer, D. E., & Dynlacht, B. D. (2014) · Nature Cell Biology · doi:10.1038/ncb3062 · Cited by 153
Histone deacetylase 11 is an ε-N-Myristoyllysine hydrolase
Moreno-Yruela, C., Galleano, I., Madsen, A. S., & Olsen, C. A. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.04.007 · Cited by 149
Development of a histone deacetylase 6 inhibitor and its biological effects
Lee, J.-H., Mahendran, A., Yao, Y., Ngo, L., Venta-Perez, G., Choy, M. L., Kim, N., Ham, W.-S., Breslow, R., & Marks, P. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313893110 · Cited by 141
“To develop HDAC6-selective inhibitors, we synthesized small molecules with bulkier and shorter linker domains than the pan-HDAC inhibitor SAHA (20, 21).”
BackgroundMethodSelf-citationFotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138
Heimburg, T., Chakrabarti, A., Lancelot, J., Marek, M., Melesina, J., Hauser, A.-T., Shaik, T. B., Duclaud, S., Robaa, D., Erdmann, F., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01478 · Cited by 124
Madsen, A. S., & Olsen, C. A. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203754 · Cited by 122
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112171 · Cited by 121
Drug discovery and development for rare genetic disorders
Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107
Cheng, F., Lienlaf, M., Wang, H.-W., Perez-Villarroel, P., Lee, C., Woan, K., Rock-Klotz, J., Sahakian, E., Woods, D., Pinilla-Ibarz, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302778 · Cited by 106
Epigenetic drugs as immunomodulators for combination therapies in solid tumors
Sigalotti, L., Fratta, E., Coral, S., & Maio, M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.015 · Cited by 102
Baud, M. G. J., Leiser, T., Haus, P., Samlal, S., Wong, A. C., Wood, R. J., Petrucci, V., Gunaratnam, M., Hughes, S. M., Buluwela, L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2016182 · Cited by 100
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics
de Waal, L., Lewis, T. A., Rees, M. G., Tsherniak, A., Wu, X., Choi, P. S., Gechijian, L., Hartigan, C., Faloon, P. W., Hickey, M. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1984 · Cited by 96
Mannan, A., Liu, C., Arsenault, P. R., Towler, M. J., Vail, D. R., Lorence, A., & Weathers, P. J. (2010) · Plant Cell Reports · doi:10.1007/s00299-009-0807-y · Cited by 75
The role of altered protein acetylation in neurodegenerative disease
Kabir, F., Atkinson, R., Cook, A. L., Phipps, A. J., & King, A. E. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1025473 · Cited by 75
Trichostatin A inhibits collagen synthesis and induces apoptosis in keloid fibroblasts
Diao, J.-S., Xia, W.-S., Yi, C.-G., Wang, Y.-M., Li, B., Xia, W., Liu, B., Guo, S.-Z., & Sun, X.-D. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-011-1140-1 · Cited by 68
General Base–General Acid Catalysis in Human Histone Deacetylase 8
Gantt, S. M. L., Decroos, C., Lee, M. S., Gullett, L. E., Bowman, C. M., Christianson, D. W., & Fierke, C. A. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01327 · Cited by 67
Becher, I., Dittmann, A., Savitski, M. M., Hopf, C., Drewes, G., & Bantscheff, M. (2014) · ACS Chemical Biology · doi:10.1021/cb500235n · Cited by 60
Decroos, C., Clausen, D. J., Haines, B. E., Wiest, O., Williams, R. M., & Christianson, D. W. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00010 · Cited by 58
Interplay between the miRNome and the epigenetic machinery: Implications in health and disease
Poddar, S., Kesharwani, D., & Datta, M. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25819 · Cited by 57
Identification of novel small molecule enhancers of protein production by cultured mammalian cells
Allen, M. J., Boyce, J. P., Trentalange, M. T., Treiber, D. L., Rasmussen, B., Tillotson, B., Davis, R., & Reddy, P. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21839 · Cited by 54
Lipponen, A., El-Osta, A., Kaspi, A., Ziemann, M., Khurana, I., KN, H., Navarro-Ferrandis, V., Puhakka, N., Paananen, J., & Pitkänen, A. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0519-z · Cited by 47
“In addition to compounds used in psychiatry, LINCS analysis revealed an anti-cancer drug, vorinostat, a histone deacetylase inhibitor (HDAC1–3 and 6) [77] as an upregulator of Cepbd.”
MethodKitir, B., Maolanon, A. R., Ohm, R. G., Colaço, A. R., Fristrup, P., Madsen, A. S., & Olsen, C. A. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00725 · Cited by 38
Mechanism of assembly, activation and lysine selection by the SIN3B histone deacetylase complex
Wan, M. S. M., Muhammad, R., Koliopoulos, M. G., Roumeliotis, T. I., Choudhary, J. S., & Alfieri, C. (2023) · Nature Communications · doi:10.1038/s41467-023-38276-0 · Cited by 32
Tago, T., & Toyohara, J. (2018) · Molecules · doi:10.3390/molecules23020300 · Cited by 28
Decroos, C., Bowman, C. M., & Christianson, D. W. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.05.045 · Cited by 17
Avendaño, C., & Menéndez, J. C. (2023) · Medicinal Chemistry of Anticancer Drugs · doi:10.1016/b978-0-12-818549-0.00019-4 · Cited by 4
Metadata
- Authors
- Marks, P. A., & Breslow, R.
- Venue
- Nature Biotechnology
- Published
- 2007-01
- Volume
- 25
- Issue
- 1
- Pages
- 84-90
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2087966689
- Cited by
- 1,196
- References
- 48
- FWCI
- 29.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.